Literature DB >> 12421731

Radiotherapy in rectal cancer.

Bengt Glimelius1.   

Abstract

Radiotherapy has an established role in the treatment of rectal cancer. In primary resectable cancer, numerous randomised trials have shown that particularly pre-operative, and to some extent also postoperative, radiotherapy substantially reduces the risk of local failure. This is seen also with total mesorectal excision. Secondary to the reduction in local failures, there is also a slight improvement in survival after pre-operative radiotherapy or postoperative radiochemotherapy. Using appropriate techniques, the morbidity of radiotherapy is low. In non-resectable cancer, radiotherapy may cause down-staging, allow surgery, and may cure some patients. Whether radiochemotherapy is more efficient has yet to be firmly established. The role of pre-operative radio(chemo)therapy to permit more sphincter-preserving procedures with adequate long-term function is not defined.

Entities:  

Mesh:

Year:  2002        PMID: 12421731     DOI: 10.1093/bmb/64.1.141

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  7 in total

Review 1.  Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.

Authors:  L E Salnikova; D S Kolobkov
Journal:  Pharmacogenomics J       Date:  2015-06-30       Impact factor: 3.550

2.  Clinical significance of tumor regression grade in rectal cancer with preoperative chemoradiotherapy.

Authors:  Young Joo Park; Byung Ryul Oh; Sang Woo Lim; Jung Wook Huh; Jae Kyun Joo; Young Jin Kim; Hyeong Rok Kim
Journal:  J Korean Soc Coloproctol       Date:  2010-08-31

Review 3.  Advances in radiotherapy in operable rectal cancer.

Authors:  Aravind Suppiah; John E Hartley; John R T Monson
Journal:  Dig Surg       Date:  2009-06-03       Impact factor: 2.588

4.  Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II).

Authors:  J Widder; F Herbst; W Dobrowsky; R Schmid; B Pokrajac; B Jech; C Chiari; A Stift; A Maier; J Karner-Hanusch; B Teleky; F Wrba; R Jakesz; R Poetter
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

5.  A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.

Authors:  Linda Kinzel; Anne Ernst; Michael Orth; Valerie Albrecht; Roman Hennel; Nikko Brix; Benjamin Frey; Udo S Gaipl; Gabriele Zuchtriegel; Christoph A Reichel; Andreas Blutke; Daniela Schilling; Gabriele Multhoff; Minglun Li; Maximilian Niyazi; Anna A Friedl; Nicolas Winssinger; Claus Belka; Kirsten Lauber
Journal:  Oncotarget       Date:  2016-07-12

Review 6.  Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?

Authors:  Grace O'Malley; Madelon Heijltjes; Aileen M Houston; Sweta Rani; Thomas Ritter; Laurence J Egan; Aideen E Ryan
Journal:  Oncotarget       Date:  2016-09-13

Review 7.  Evidence according to Cochrane Systematic Reviews on Alterable Risk Factors for Anastomotic Leakage in Colorectal Surgery.

Authors:  Bradley Wallace; Fabia Schuepbach; Stefan Gaukel; Ahmed I Marwan; Ralph F Staerkle; Raphael N Vuille-Dit-Bille
Journal:  Gastroenterol Res Pract       Date:  2020-01-03       Impact factor: 2.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.